↓ Skip to main content

Dove Medical Press

Article Metrics

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective

Overview of attention for article published in Breast cancer targets and therapy, November 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
32 Mendeley
Title
Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
Published in
Breast cancer targets and therapy, November 2012
DOI 10.2147/bctt.s37003
Pubmed ID
Authors

Thomas Einarson, Machado

Abstract

To evaluate, from the perspective of the Brazilian public health care system, the cost-effectiveness of lapatinib plus capecitabine (LAP/CAP) versus capecitabine alone (CAP) or trastuzumab plus capecitabine (TRAST/CAP) in the treatment of women with human epidermal growth factor receptor-2-positive metastatic breast cancer previously treated with trastuzumab.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 3%
Ecuador 1 3%
Unknown 30 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 19%
Unspecified 5 16%
Student > Ph. D. Student 4 13%
Researcher 4 13%
Student > Postgraduate 3 9%
Other 10 31%
Readers by discipline Count As %
Medicine and Dentistry 11 34%
Unspecified 6 19%
Pharmacology, Toxicology and Pharmaceutical Science 4 13%
Biochemistry, Genetics and Molecular Biology 3 9%
Social Sciences 3 9%
Other 5 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2012.
All research outputs
#1,993,715
of 4,506,116 outputs
Outputs from Breast cancer targets and therapy
#21
of 61 outputs
Outputs of similar age
#30,687
of 80,134 outputs
Outputs of similar age from Breast cancer targets and therapy
#3
of 5 outputs
Altmetric has tracked 4,506,116 research outputs across all sources so far. This one has received more attention than most of these and is in the 53rd percentile.
So far Altmetric has tracked 61 research outputs from this source. They receive a mean Attention Score of 2.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 80,134 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.